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Abstract
Background: According to the WHO report in 2015, obesity is the fifth leading cause of death worldwide, and the
prevalence of Egyptian female obesity is 37.5 %. Since obesity is highly influenced by genetics, and adipose tissue
renin-angiotensin system is over-activated in obesity, the effect of angiotensin-converting enzyme (ACE) insertion/
deletion (I/D) polymorphism on obesity and related disorders was studied in several populations, because of its
effect on ACE activity. Our objective was to study the association of ACE I/D polymorphism with obesity and certain
related disorders, namely hypertension, insulin resistance and metabolic syndrome, in Egyptian females.
Methods: Eighty female volunteers were recruited, blood pressure and body measurements were recorded and a
fasting blood sample was obtained for the quantitation of glucose, lipid profile, insulin, leptin and identification of
ACE I/D polymorphs. Subjects were grouped based on hypertension and obesity states. Comparisons of continuous
parameters were made with independent sample t-test between two groups. The frequencies of ACE genotypes
and alleles, and the association between gene polymorphism and metabolic parameters were assessed using
chi-square or Fisher's exact test.
Results: Genotype frequencies were in Hardy-Weinberg equilibrium for all groups. Genotype distribution did not
differ significantly between controls and cases of all the studied disorders. Although DD carriers had apparently
higher parameters of blood pressure, lipid profile and insulin resistance, only diastolic blood pressure was almost
significant (p = 0.057). I-carriers were significantly less susceptible to hypertension than DD carriers having normal
waist/hip ratio (p = 0.007, OR = 17.29, CI = 1.81–164.96) and normal conicity index (p = 0.024, OR = 7.00, CI = 1.36–35.
93). In DD genotype carriers, a significant association was found between insulin resistance and high body mass
index (p = 0.004, OR = 8.89, CI = 1.94–40.71), waist circumference (p = 0.003, OR = 9.63, CI = 2.14–43.36) and waist/
height ratio (p = 0.034, OR = 6.86, CI = 1.25–37.61), although the variations in percentages between DD and I-carriers
were not high enough to conclude an effect of ACE I/D on such an association.
Conclusions: In this sample of Egyptian females, ACE I/D polymorphism was not significantly associated with
obesity nor with any of its related disorders studied. The I allele seemed protective against hypertension in subjects
with normal, not high, waist/hip ratio and conicity index compared to DD genotype carriers.
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Background
The worldwide prevalence of obesity more than doubled
between 1980 and 2014. According to the WHO health
profile of Egypt, the prevalence of adult female obesity
in Egypt (37.5 %) was much higher than the Eastern
Mediterranean regional average (26.4 %) which, in turn,
was higher than the global average (20.5 %). On the
other hand, male obesity showed less prevalence in
Egypt (20.3 %), but comparable regional and global aver-
ages (27.5 % and 24 %, respectively). The profile also
mentioned that the mean body mass index (BMI) in
Egyptian adult females was 30.7 while the global average
for females was 24.6 [1].
Raised BMI is a major risk factor for non-communicable
diseases such as cardiovascular diseases, which were
the leading cause of death in 2012, diabetes, musculo-
skeletal disorders and some cancers. Most of the
world's population live in countries where overweight
and obesity cause higher mortality than underweight
[1]. Hypertension is the most frequent disease that ac-
companies obesity, and BMI is a significant predictor of
high blood pressure even in non-obese populations.
The converse is also true, a higher blood pressure pre-
dicts future obesity in Egyptian adolescents [2]. Obesity
is also associated with glucose intolerance and fasting
hyperinsulinemia [3]. In addition, abdominal obesity
and hypertension were the most common abnormalities
responsible for the high prevalence of metabolic syn-
drome (MetS) in women in many populations [4].
Leptin is a peptide expressed and secreted by adipocytes.
It serves an “adipostat” function that regulates fat mass by
decreasing food intake and increasing energy expenditure
or thermogenesis. Leptin was found to be related to obes-
ity, hypertension and insulin resistance [5].
Angiotensin-converting enzyme (ACE), a key enzyme in
the renin-angiotensin system (RAS), catalyzes the conver-
sion of the decapeptide angiotensin I to the potent vaso-
pressor octapeptide angiotensin II (Ang II) [6–8]. The
ACE gene consists of 26 exons and spans 21 kb on the
long arm of chromosome 17 (17q23.3). It has a common
“indel” polymorphism characterized by the insertion/pres-
ence (I allele) or deletion/absence (D allele) of a 287-bp
Alu repeat sequence in intron 16. ACE activity in individ-
uals with DD genotype is 65 % higher than those with II
genotypes, while subjects with ID genotype have 31 %
higher ACE activity than II homozygotes [6–8]. The com-
ponents of over-activated RAS produced by adipocytes
provide a potential pathway through which obesity leads
to hypertension and insulin resistance [9].
Research on the genetic architecture of complex traits
such as obesity should be designed and analyzed in a sex-
specific way so that data can be separately examined in
both men and women [10]. In most WHO regions, women
had roughly double the obesity prevalence of men [1].
Another reason is sex-related physical dimorphism gener-
ally conceptualized as android versus gynoid distributions
of adipose tissue; with females having an hourglass body
shape (smaller waist/hip ratio "WHR") whilst males having
an inverted triangle shape (larger WHR) [10].
ACE I/D polymorphism association with hypertension
has been extensively studied among different populations,
and associations with obesity and insulin resistance have
also been studied to a lesser extent. In this context, ACE
I/D polymorphism association studies in Egyptians are
very limited, with few reports linking it to hypertension
and diabetes [11, 12], but none of them addressed its cor-
relation with obesity. Also, very few studies were con-
ducted on Arabs and Africans, but not on Egyptians, that
concurrently assessed all these disorders in relation to
ACE I/D polymorphism [13, 14]. Moreover, there are no
reports, to date, on the association of ACE gene I/D poly-
morphism with MetS in Arabs or Africans.
Therefore, the aim of the present work was to investi-
gate the association of obesity and its related disorders,
namely hypertension, insulin resistance and MetS, with
ACE I/D polymorphism in Egyptian females comparing
it with Arabic and African studies.
Methods
The study was conducted on 80 adult non-pregnant fe-
males chosen from the outpatient clinic at the Internal
Medicine Department, Kasr El-Aini Hospital, affiliated
to Cairo University. Participants ranged in age from 30–
65 years. Subjects who had hematologic, renal, hepatic
or thyroid diseases were excluded. For each participant,
full medical and family history, anthropometric measure-
ments and blood pressure were recorded, in addition to
taking a fasting blood sample (samples were collected
during the period from April to December 2010).
Anthropometric measurements
Body weight was measured with light clothing and shoes
off using electronic scales. Non-stretchable tape was used
to take height, which was measured in an upright standing
position without shoes, waist circumference (WC), which
was measured at the midpoint between the bottom of the
ribs and the top of the iliac crest at the level of the umbil-
icus, and hip circumference which was measured at the
largest posterior extension of the buttocks.
Blood pressure
For systolic and diastolic blood pressure (SBP and DBP)
measurements, auscultation method was performed on
the left upper arm in sitting position after resting for at
least 15 min using a mercury sphygmomanometer and a
stethoscope, according to the American Heart Associ-
ation recommendations [15].
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Blood sampling
A 12 h-fasting blood sample was then taken and divided
into 3 portions for further analysis: 2 ml of blood was col-
lected on EDTA for the detection of ACE gene poly-
morphism, 1 ml was fluorinated for the determination of
fasting blood glucose level, and 2 ml was used to separate
serum for the assay of insulin, leptin and lipid profile.
Molecular biology techniques
Genomic DNA was extracted and purified from whole
peripheral blood samples using QIAamp DNA mini kit
(Qiagen Inc., Valencia, CA, USA) and stored at −80 °C
in aliquots until required. Amplification of the ACE gene
was carried out by polymerase chain reaction (PCR)
using Taq PCR Master Mix (Qiagen, Valencia, CA, USA)
and T-Gradient thermal cycler (Biometra, Germany).
The sequence of primers used for amplification of ACE
was 5'-CTGGAGACCACTCCCATCCTTTCT-3' (forward)
and 5'-GATGTCGCCATCACATTCGTCAGAT-3' (re-
verse). Amplification of the I allele is sometimes sup-
pressed in ID genotype samples giving rise to mistyping of
ID as DD in approximately 5 % of cases. To avoid such
mistyping, samples of the DD genotype were subjected to a
second independent PCR with primers that recognize an
insertion-specific sequence: 5'-TGGGACCACAGCGCC
CGCCACTAC-3' (forward) and 5'-TCGCCAGCCCTCC
CATGCCCATAA-3' (reverse). Electrophoresis was then
performed on 2 % agarose gels stained with Red-Safe and
the electrophoretic products were visualized using ultra-
violet light trans-illumination. The PCR product was either
490 bp insertion (I allele) or 190 bp deletion (D allele). The
second PCR with the insertion-specific primers yielded a
335 bp DNA product in the presence of the I allele, and no
product for homozygous DD samples.
Biochemical laboratory investigations
For the assay of plasma glucose level, the kit for enzymatic-
colorimetric determination, supplied by STANBIO labora-
tory (Boerne, TX, USA), was used. Serum triglycerides
(TG) level was determined by an enzymatic-colorimetric
method using a kit supplied by PIONTE SCIENTIFIC Inc.
(Canton, MI, USA). Serum total cholesterol (TC) level was
determined by an enzymatic-colorimetric method using a
kit supplied by LABKIT (Chemelex, SA, Spain). Serum
high density lipoproteins (HDL) level was determined
using HDL cholesterol precipitating kit supplied by
CHRONOLAB (Barcelona, Spain). Low density lipopro-
teins (LDL) level was calculated using the Friedewald equa-
tion: LDL =TC – HDL – (TG/5).
Enzyme-linked immunosorbent assay (ELISA)
Serum level of leptin was determined using a solid phase
Enzyme Amplified Sensitivity Immunoassays (EASIA) kit
supplied by DiaSource Europe S.A (Nivelles, Belgium). Its
detection limit was 0.04 ng/ml, the inter-assay coefficient
of variance (CV) was 10.2–12.7 % and the intra-assay CV
was 3.5–13.3 %. Insulin was assayed using an ELISA kit
supplied by Quantikine (Shanghai, China) that employed a
quantitative sandwich enzyme immunoassay technique.
Its detection limit was 0.881 pmol/L, the inter-assay CV
was 6.9–7.5 % and the intra-assay CV was 3.7–4.0 %.
Calculated indices
Several indices were calculated for each subject includ-
ing indices for blood pressure [mean arterial pressure
"MAP" and pulse pressure "PP" [16], insulin resistance
[homeostasis model assessment "HOMA", quantitative
insulin sensitivity check index "QUICKI" and fasting glu-
cose insulin ratio "FGIR" [17], adiposity [body mass
index “BMI”, waist/hip ratio “WHR”, waist/height ratio
"WHtR", and conicity index "C-index, a measure of ab-
dominal obesity calculated as: Waist circumference(m)/
0.109 √ [weight(Kg)/ height(m)]" [5]] and lipid ratios
[TC/HDL and LDL/HDL].
Subjects grouping
The studied individuals were classified into four groups
based on both BMI and hypertension state [obese hyper-
tensive patients (OH, n = 28), obese normotensive patients
(ON, n = 23), lean hypertensive patients (LH, n = 12) and
lean normotensive controls (LN, n = 17)]. Subjects were
also divided into 2 categories based on each of hyperten-
sion, BMI, WC, WHR, WHtR, HOMA and MetS. The cut-
offs used for categorization were: SBP ≥ 140 or DBP ≥ 90
for hypertension [15], BMI ≥ 26 [18], WC ≥ 92 cm [19],
WHR ≥ 0.85 [20], WHtR ≥ 0.52 [21], C-index ≥ 1.31 [22],
and HOMA ≥ 3.5 [23]. Metabolic syndrome was considered
for patients having at least 3 of 5 criteria: increased WC " ≥
92 cm for the Egyptian population", SBP ≥ 130 mmHg
and/or DBP ≥ 85 mmHg, fasting glucose ≥ 100 mg/dl,
TG ≥ 150 mg/dl and HDL < 50 mg/dl in women [4].
Statistical analyses
Prior to association analyses, the significance of devia-
tions of observed genotype frequencies from those pre-
dicted by the Hardy–Weinberg equation were evaluated
using chi square tests. Data are presented as mean
(standard deviation) for quantitative variables, and as
numbers (percentages) for categorical variables. The
sample size achieved moderate effect size of 0.4 and the
power of statistics was 0.8 at p < 0.05. Comparisons of
the continuous parameters were made with independ-
ent sample t-test between two groups. The frequen-
cies of ACE genotypes and alleles, and the association
between the gene polymorphism and metabolic pa-
rameters were assessed using the chi-square test.
Fisher's exact test was used instead of chi-square test
for comparing categorical data when more than 20 %
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of the expected frequencies were less than 5. For such
significant associations, risk estimate was presented as
unadjusted odds ratios (OR) and confidence intervals
(CI). A value of p < 0.05 (two-tailed) was considered
significant. All the statistical analyses were carried out
using SPSS (Chicago, IL, USA) software, version 17.0
for Microsoft Windows.
Results
The studied sample of the Egyptian population com-
prised 80 females whose ages ranged from 30–65 years,
with an average age of 48.8 years. There was no signifi-
cant difference in age among different groups. The dis-
tribution of polymorphs within this 80-subject sample
was 62.5 % DD (50 subjects), 31.25 % ID (25 subjects)
and 6.25 % II (5 subjects). Allele frequencies were 78.1 %
for the D allele and 21.9 % for the I allele. Genotype dis-
tributions within the pooled sample and among different
groupings were all in Hardy-Weinberg equilibrium in
cases as well as in controls (Table 1).
Despite apparently higher values of blood pressure and
lipid profile parameters in DD genotype carriers, no sig-
nificant difference was observed between DD genotype
and I-carriers for all tested parameters, namely blood
pressure, lipid profile, insulin resistance and weight-
related parameters, using t-test for comparison, except for
diastolic blood pressure which showed an almost signifi-
cant elevation in DD genotype carriers as compared to
I-carriers (p = 0.057, Table 2).
In order to apply the chi-square test of association, we
converted the continuous data of blood pressure, certain
obesity indices, HOMA and MetS into categorical data
so that subjects could be distributed into two groups for
each parameter. The results of the association tests are
summarized in Table 3 where the significance level
exceeded 0.05 for all tested groups based on blood pres-
sure, BMI, WC, WHR, WHtR, C-index, HOMA and
MetS. Groups based on being obese, hypertensive or
both had apparently higher frequencies of the DD geno-
type than controls but such differences did not reach
statistical significance.
Studying the possible relationship between obesity and
hypertension, we found that among the different obesity
indices studied, only WHR and C-index showed signifi-
cant difference between hypertensive and normotensive
subjects (p < 0.05, Table 4). Also, patients having higher
Table 1 Hardy-Weinberg equilibrium for ACE I/D genotypes
Groupings (n) Observed frequencies Expected frequencies χ2 p
DD ID II DD ID II
All 80 subjects 50 25 5 48.8 27.3 3.8 0.590 0.443
OH (28) 19 7 2 18.1 8.8 1.1 1.212 0.271
ON (23) 14 7 2 13.3 8.4 1.3 0.616 0.433
LH (12) 9 3 0 9.2 2.6 0.2 0.245 0.621
LN (17) 8 8 1 8.5 7.1 1.5 0.302 0.583
Hypertensive (40) 28 10 2 27.2 11.6 1.2 0.720 0.396
Normotensive (40) 22 15 3 21.8 15.5 2.8 0.040 0.842
High BMI (51) 33 14 4 31.4 17.3 2.4 1.915 0.178
Normal BMI (29) 17 11 1 17.5 10.1 1.5 0.238 0.686
High WC (57) 37 16 4 35.5 18.9 2.5 1.379 0.240
Normal WC (23) 13 9 1 13.3 8.4 1.3 0.130 0.718
High WHR (55) 37 15 3 36.0 17.0 2.0 0.755 0.385
Normal WHR (25) 13 10 2 13.0 10.1 2.0 0.002 0.968
High WHtR (69) 43 21 5 41.5 24.0 3.5 1.101 0.294
Normal WHtR (11) 7 4 0 7.4 3.3 0.4 0.543 0.461
High C-index (44) 32 10 2 31.1 11.8 1.1 0.998 0.318
Normal C-index (36) 18 15 3 18.1 14.9 3.1 0.003 0.959
Insulin Resistant (62) 39 21 2 39.5 20.0 2.5 0.168 0.681
Insulin Sensitive (18) 11 4 3 9.4 7.2 1.4 3.583 0.058
MetS (45) 27 15 3 26.5 16.1 2.5 0.210 0.647
No MetS (35) 23 10 2 22.4 11.2 1.4 0.402 0.526
OH obese hypertensive, ON obese normotensive, LH lean hypertensive, LN lean normotensive, BMI body mass index, WC waist circumference, WHR waist/hip ratio,
WHtR waist/height ratio, C-index conicity index, MetS metabolic syndrome, DD homozygous deletion genotype, ID heterozygous insertion deletion genotype, II
homozygous insertion genotype, χ2: chi-square test statistic
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WHR and WC had significantly higher blood pressure
parameters than those with normal WHR or WC (both
at p < 0.05), whereas other obesity classifications did not
show that difference except for C-index that showed sig-
nificant correlation with pulse pressure only (Table 5).
As shown in Table 6, we also found that this high risk of
being hypertensive in patients with high WHR was com-
parable in both DD and I-carriers (62.16 % and 61.11 %
hypertensives, respectively). On the other hand, it was
noticed that normal WHR subjects had much less odds
of developing hypertension in I-carriers (only 8.3 % hy-
pertensives) than in DD subjects (38.46 % hypertensives).
Such effect of the I-allele in lowering the susceptibility of
normal WHR subjects to hypertension was highly
significant at p = 0.007 with odds ratio (OR) = 17.29 and
confidence interval (CI) = 1.813–164.96. The same pro-
tective effect of the I-allele against hypertension was no-
ticed when using the C-index to represent the obesity
state, with comparable percentages of hypertensives in lar-
ger C-index DD and I-carriers (59.38 % and 66.67 %, re-
spectively), while chances of being hypertensive were
significantly lower in normal C-index I-carriers (22.22 %)
than the corresponding DD counterparts (50.0 %) at
p = 0.024 with OR = 7.00 and CI = 1.36–35.93. When
using other indices to represent the obesity state, there
was no significant χ2 association between obesity and
hypertension at any polymorph comparison (Table 6).
Table 4 shows the significant difference in weight-related
parameters between insulin-resistant and insulin-sensitive
groups (p˂0.05), except for WHR and C-index. In addition,
based on different obesity indices, we found that obesity
classified by BMI, WC and WHtR showed highly significant
χ2 association with insulin resistance (using HOMA cut-
off) only in the DD polymorph at p = 0.004, OR = 8.89 and
CI = 1.94–40.71 for BMI, at p = 0.003, OR = 9.63 and
CI = 2.14–43.36 for WC and at p = 0.034, OR = 6.86
and CI = 1.25–37.61 for WHtR. WHR and C-index
showed no significant χ2 association with insulin re-
sistance (Table 6).
Discussion
In the current study on Egyptian females, the association
of ACE I/D polymorphism with obesity and several related
disorders was studied. The ages of the studied subjects
were generally homogenous. The distribution of poly-
morphs within this 80-subject sample was comparable
to that reported in a previous study conducted on the
Egyptian population [24].
As depicted in Tables 2 and 3, weight-related parameters
and leptin did not differ significantly among ACE poly-
morphs (DD, I-carriers). Also, comparing the frequency of
ACE genotypes or alleles between obese and lean groups
did not show significant difference. So, no significant asso-
ciation between ACE I/D polymorphism and obesity was
suggested. However, there seems to be some tendency to-
wards obesity in DD genotype carriers as manifested by
apparently higher DD genotype frequencies in obese sub-
jects compared to their corresponding controls based on
all obesity classifications. Also, there was no significant
difference in blood pressure parameters between ACE
polymorphs, although DD carriers had non-significantly
higher blood pressure parameters than I-carriers with the
difference in DBP being almost significant. Moreover, the
distribution of the DD genotype was apparently higher in
hypertensives than in normotensives but did not reach
statistical significance. Thus, association of ACE I/D poly-
morphism with hypertension in the currently studied sub-
jects cannot be suggested strongly enough. No significant
Table 2 Comparison of different parameters between DD and
I-carriers using t-test
DD (50) ID + II (30) t p
Age (years) 49.62 (7.42) 46.57 (9.60) 1.50 0.14
SBP (mmHg) 133.20 (19.69) 128.17 (16.74) 1.17 0.25
DBP (mmHg) 85.30 (12.43) 81.00 (7.47) 1.93 0.057
MAP (mmHg) 101.27 (14.45) 96.72 (9.97) 1.66 0.10
PP (mmHg) 47.90 (10.26) 47.17 (11.87) 0.29 0.77
Weight (Kg) 76.26 (21.43) 77.35 (26.06) −0.20 0.84
Height (cm) 154.72 (7.16) 156.03 (5.39) −0.87 0.39
WC (cm) 101.26 (16.15) 98.97 (15.73) 0.62 0.53
Hip (cm) 110.84 (14.49) 111.27 (18.40) −0.12 0.91
BMI (Kg/m2) 31.68 (8.37) 31.56 (9.88) 0.06 0.96
WHR 0.91 (0.08) 0.89 (0.10) 0.95 0.35
WHtR 0.65 (0.10) 0.63 (0.10) 0.88 0.38
C-index 1.34 (0.09) 1.31 (0.13) 0.97 0.33
Leptin (ng/ml) 9.50 (6.26) 9.60 (8.07) −0.06 0.95
TC (mg/dl) 166.00 (30.50) 159.07 (30.86) 0.98 0.33
TG (mg/dl) 87.90 (35.36) 76.80 (24.55) 1.51 0.13
LDL (mg/dl) 111.64 (27.78) 105.70 (30.29) 0.89 0.37
HDL (mg/dl) 37.14 (9.50) 37.87 (7.58) −0.36 0.72
TC/HDL 4.69 (1.22) 4.36 (1.18) 1.16 0.25
LDL/HDL 3.19 (1.10) 2.93 (1.07) 1.02 0.31
Glucose (mg/dl) 103.88 (20.90) 104.40 (18.47) −0.11 0.91
Insulin (μIU/ml) 18.81 (4.72) 17.59 (4.93) 1.10 0.27
HOMA 4.87 (1.82) 4.56 (1.69) 0.77 0.44
QUICKI 0.306 (0.01) 0.308 (0.01) −0.81 0.42
FGIR 5.81 (1.77) 6.30 (1.89) −1.17 0.25
Data are presented as mean (SD)
SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial
pressure, PP pulse pressure, WC waist circumference, BMI body mass index,
WHR waist/hip ratio, WHtR waist/height ratio, C-index conicity index, TC total
cholesterol, TG triglycerides, LDL low density lipoproteins, HDL high density
lipoproteins, HOMA homeostasis model of assessment, QUICKI quantitative
insulin sensitivity check index, FGIR fasting glucose insulin ratio, DD
homozygous deletion genotype, ID heterozygous insertion deletion genotype,
II: homozygous insertion genotype, t: t-test statistic
Motawi et al. Nutrition & Metabolism  (2016) 13:68 Page 5 of 11
Table 3 Association of ACE(I/D) genotype/allele frequencies with hypertension, obesity, insulin resistance and metabolic syndrome
Groups (n) DD ID + II Significance D allele I allele Significance
OH (28) 19 (67.9 %) 9 (32.1 %) χ2 = 2.898
p = 0.41
45 (80.4 %) 11 (19.6 %) χ2 = 2.64
p = 0.45
ON (23) 14 (60.9 %) 9 (39.1 %) 35 (76.1 %) 11 (23.9 %)
LH (12) 9 (75.0 %) 3 (25.0 %) 21 (87.5 %) 3 (12.5 %)
LN (17) 8 (47.1 %) 9 (53.9 %) 24 (70.6 %) 10 (29.4 %)
Obese BMI (51) 33 (64.7 %) 18 (35.3 %) χ2 = 0.29
p = 0.59
80 (78.4 %) 22 (21.6 %) χ2 = 0.015
p = 0.90
Normal BMI (29) 17 (58.6 %) 12 (41.4 %) 45 (77.6 %) 13 (22.4 %)
Large WC (57) 37 (64.9 %) 20 (35.1 %) χ2 = 0.49
p = 0.48
90 (78.9 %) 24 (21.1 %) χ2 = 0.16
p = 0.69
Normal WC (23) 13 (56.5 %) 10 (43.5 %) 35 (76.1 %) 11 (23.9 %)
Large WHR (55) 37 (67.3 %) 18 (32.7 %) χ2 = 1.71
p = 0.19
89 (80.9 %) 21 (19.1 %) χ2 = 1.6
p = 0.21
Normal WHR (25) 13 (52.0 %) 12 (48.0 %) 36 (72.0 %) 14 (28.0 %)
Large WHtR (69) 43 (62.3 %) 26 (37.7 %) Fisher's Exact:
p = 1.00
107 (77.5 %) 31 (22.5 %) χ2 = 0.20
p = 0.65
Normal WHtR (11) 7 (63.6 %) 4 (36.4 %) 18 (81.8 %) 4 (18.2 %)
Large C-index (44) 32 (72.7 %) 12 (27.3 %) χ2 = 3.26
p = 0.071
74 (84.1 %) 14 (15.9 %) χ2 = 3.07 p = 0.08
Normal C-index (36) 18 (50.0 %) 18 (50.0 %) 51 (70.8 %) 21 (29.2 %)
Hypertensive (40) 28 (70.0 %) 12 (30.0 %) χ2 = 1.92
p = 0.17
66 (82.5 %) 14 (17.5 %) χ2 = 1.79
p = 0.18
Normotensive (40) 22 (55.0 %) 18 (45.0 %) 59 (73.8 %) 21 (26.2 %)
Insulin resistant (62) 39 (62.9 %) 23 (37.1 %) χ2 = 0.02
p = 0.89
99 (79.8 %) 25 (20.2 %) χ2 = 0.95
p = 0.33
Insulin sensitive (18) 11 (61.1 %) 7 (38.9 %) 26 (72.2 %) 10 (27.8 %)
Positive MetS (45) 27 (60.0 %) 18 (40.0 %) χ2 = 0.27
p = 0.6
69 (76.7 %) 21 (23.3 %) χ2 = 0.26
p = 0.61
No MetS (35) 23 (65.7 %) 12 (34.3 %) 56 (80.0 %) 14 (20.0 %)
Data are presented as number (percentage), n (%)
OH obese hypertensive subjects, ON obese normotensive subjects, LH lean hypertensive subjects, LN lean normotensive control subjects, BMI body mass index,
WC waist circumference, WHR waist/hip ratio, WHtR waist/height ratio, C-index conicity index, MetS metabolic syndrome, DD homozygous deletion genotype, ID
heterozygous insertion deletion genotype, II homozygous insertion genotype, D deletion allele, I insertion allele
Table 4 Comparison of certain obesity-related parameters between groups based on hypertension and insulin resistance
Hypertensive (40) Normotensive (40) Insulin resistant (62) Insulin sensitive (18)
Weight (Kg) 76.36 (22.65) 76.98 (23.86) 80.1 (21.29) 64.86 (25.81)
t = −0.12, p = 0.91 t = 2.55, p = 0.013*
WC (cm) 102.28 (14.53) 98.53 (17.21) 102.63 (15.09) 92.72 (16.8)
t = 1.05, p = 0.30 t = 2.39, p = 0.019*
Hip (cm) 110.23 (15.92) 111.78 (16.16) 113.53 (15.14) 102.28 (16.01)
t = −0.43, p = 0.67 t = 2.74, p = 0.008*
BMI (Kg/m2) 31.55 (8.18) 31.72 (9.67) 32.96 (8.42) 27.07 (9.23)
t = −0.09, p = 0.93 t = 2.56, p = 0.013*
WHR 0.93 (0.09) 0.88 (0.07) 0.905 (0.085) 0.908 (0.089)
t = 2.83, p = 0.01* t = −0.11, p = 0.91
WHtR 0.66 (0.09) 0.63 (0.11) 0.66 (0.1) 0.6 (0.1)
t = 1.21, p = 0.23 t = 2.17, p = 0.033*
C-index 1.36 (0.10) 1.30 (0.10) 1.324 (0.105) 1.336 (0.104)
t = 2.43, p = 0.02* t = −0.38, p = 0.708
Data are presented as mean (SD)
*: significant difference at p < 0.05
WC waist circumference, BMI body mass index, WHR waist/hip ratio, WHtR waist/height ratio, C-index conicity index, t: t-test statistic
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difference was observed in glucose level or insulin resist-
ance indices among ACE polymorphs, and the genotype
and allele frequencies did not vary between insulin resist-
ant and normal subjects. Lipid profile parameters did not
differ significantly among genotypes, although subjects
with the DD genotype showed slightly higher values than
I-carriers. Finally, no association was found between ACE
I/D polymorphism and MetS. Thus, it can be concluded
that ACE I/D polymorphism was not significantly associ-
ated with obesity or any of the studied related disorders in
this sample of Egyptian females.
Angiotensin-converting enzyme is a key player in the
RAS as it catalyzes the conversion of angiotensin I to
angiotensin II (Ang II). The ACE gene I/D polymorph-
ism markedly affects ACE activity, where DD genotype
carriers have 65 % higher ACE activity than those with
the II genotype, and subjects with the ID genotype have
31 % higher activity than II homozygotes [6]. Owing to
the principal role of ACE in the RAS, alterations in its ac-
tivity, associated with its I/D polymorphism, will signifi-
cantly affect the RAS. Over-activated systemic and
adipose tissue RAS components provide a potential path-
way through which obesity may lead to hypertension and
insulin resistance, and through which ACE I/D poly-
morphism may be related to these disorders [9]. Activa-
tion of RAS may lead to obesity through the secretion of
Ang II by mature adipocytes. Angiotensin II stimulates
the differentiation of pre-adipocytes into mature adipo-
cytes (hyperplasia) and increases lipid content of mature
adipocytes (hypertrophy) by stimulation of lipogenesis and
inhibition of lipolysis [25], and possibly through reducing
adipose tissue blood flow [9]. Activation of the RAS may
also contribute to insulin resistance in Ang II-responsive
tissues [9], firstly by decreasing the percentage of small
insulin-sensitive adipocytes in comparison to larger ma-
ture and relatively insulin-resistant cells, and secondly by
reducing blood flow which reduces insulin and glucose
delivery to the insulin-sensitive tissues [26]. Accordingly,
the apparent predisposition of DD genotype carriers,
in the present study, to obesity, hypertension and dis-
rupted lipid profile could be justified by the aforesaid
fact that the DD genotype has the highest ACE activ-
ity among all ACE I/D polymorphs. However, these
relationships were only apparent and could not reach
the accepted level of significance most likely due to
our relatively small sample size.
Previous studies on ACE I/D polymorphism associ-
ation with diseases mainly obesity and hypertension are
too many worldwide. We herein compare our results
with studies conducted on Arab and African populations
which are remarkably limited in this regard. However,
generally, the genetic association studies are sometimes
controversial even within the same population [27, 28].
Very few studies considered the association of obesity
with ACE I/D polymorphism in Arabs and Africans,
where no association was found, similar to our findings, in
Saudis [27] and Tunisians [13], while another study de-
tected an association with the DD genotype in Saudis [28].
Regarding association studies of ACE I/D polymorphism
with hypertension, only two studies were conducted on
Table 5 Comparison of leptin and blood pressure parameters between different obesity classifications, using t-test
Leptin (μIU/ml) SBP (mmHg) DBP (mmHg) MAP (mmHg) PP (mmHg)
Large BMI 12.43 (6.96) 132.98 (16.43) 85.29 (10.36) 101.19 (11.85) 47.69 (9.73)
Normal BMI 4.17 (1.83) 128.21 (22.29) 80.71 (11.68) 96.55 (14.84) 47.50 (12.80)
t = 8.06, p < 0.001* t = 0.99, p = 0.33 t = 1.80, p = 0.08 t = 1.53, p = 0.13 t = 0.07, p = 0.95
Large WC 11.67 (7.10) 134.21 (17.37) 85.79 (10.51) 101.93 (12.25) 48.42 (10.40)
Normal WC 4.26 (1.97) 124.13 (20.26) 78.48 (10.60) 93.70 (13.45) 45.56 (11.80)
t = 7.22, p < 0.001* t = 2.24, p = 0.03* t = 2.81, p = 0.01* t = 2.65, p = 0.01* t = 1.04, p = 0.30
Large WHR 9.45 (6.19) 134.55 (18.35) 85.18 (11.04) 101.64 (12.87) 49.38 (11.20)
Normal WHR 9.76 (8.59) 123.75 (17.59) 80.21 (10.27) 94.72 (12.49) 43.54 (8.78)
t = −0.16, p = 0.78 t = 2.44, p = 0.02* t = 1.88, p = 0.06 t = 2.22, p = 0.03* t = 2.27, p = 0.03*
Large WHtR 10.51 (6.99) 132.54 (18.30) 84.42 (10.87) 100.46 (12.84) 48.12 (10.71)
Normal WHtR 3.47 (0.91) 123.64 (20.14) 79.09 (11.14) 93.94 (13.73) 44.55 (11.50)
t = 7.95, p < 0.001* t = 1.48, p = 0.14 t = 1.51, p = 0.14 t = 1.55, p = 0.13 t = 1.02, p = 0.31
Large C-index 9.07 (6.37) 133.75 (18.40) 83.64 (10.64) 100.34 (12.65) 50.11 (11.28)
Normal C-index 10.11 (7.63) 128.33 (18.86) 83.75 (11.55) 98.61 (13.69) 44.58 (9.52)
t = −0.67, p = 0.51 t = 1.29, p = 0.20 t = −0.05, p = 0.96 t = 0.59, p = 0.56 t = 2.34, p = 0.02*
Data are presented as mean (SD)
*: significant difference at p < 0.05
SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pressure, PP pulse pressure, BMI body mass index, WC waist circumference, WHR
waist/hip ratio, WHtR waist/height ratio, C-index conicity index, t: t-test statistic
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Egyptians and they associated the D allele with hyperten-
sion [11], mainly on noise exposure [12]. In Arabs, no cor-
relation with hypertension was found in Emirates [29], in
Lebanon [30] nor in Algeria [31]. When an association was
found, hypertension was accompanied by other factors
such as age in Lebanese [32], obesity in Tunisians [13] and
Emiratis [14] or diabetes and obesity in Saudi patients [8].
Limited studies were also conducted in Arabs and
Africans investigating the association of ACE I/D poly-
morphism with insulin resistance whereby no associ-
ation was observed in Emiratis [14], Lebanese [33]
nor in Tunisians [34]. On the other hand, the D allele
was associated with insulin resistance in an earlier study
on Egyptians [11]. Also, the DD genotype distribution was
Table 6 Associations of obesity (based on different obesity indices) with hypertension and insulin resistance layered by
I/D genotypes
Polymorph Obesity Hypertension Insulin resistance
Hypertensive Normotensive Resistant Sensitive
DD Large WHR (37) 23 (62.2 %) 14 (37.8 %) 30 (81.1 %) 7 (18.9 %)
Normal WHR (13) 5 (38.5 %) 8 (61.5 %) 9 (69.2 %) 4 (30.8 %)
χ2 = 2.19, p = 0.14 Fisher's exact: p = 0.45
I-carriers Large WHR (18) 11 (61.1 %) 7 (38.9 %) 14 (77.8 %) 4 (22.2 %)
Normal WHR (12) 1 (8.3 %) 11 (91.7 %) 9 (75.0 %) 3 (25.0 %)
Fisher's exact: p = 0.007*
OR = 17.29, CI = 1.81–164.96
Fisher's exact: p = 1.00
DD Large C-index (32) 19 (59.4 %) 13 (40.6 %) 25 (78.1 %) 7 (21.9 %)
Normal C-index (18) 9 (50.0 %) 9 (50.0 %) 14 (77.8 %) 4 (22.2 %)
χ2 = 0.41, p = 0.52 Fisher's exact: p = 1.00
I-carriers Large C-index (12) 8 (66.7 %) 4 (33.3 %) 9 (75.0 %) 3 (25.0 %)
Normal C-index (18) 4 (22.2 %) 14 (77.8 %) 14 (77.8 %) 4 (22.2 %)
Fisher's exact: p = 0.024*
OR = 7.00, CI = 1.36–35.93
Fisher's exact: p = 1.00
DD Obese BMI (33) 19 (57.6 %) 14 (42.4 %) 31 (91.2 %) 3 (8.8 %)
Normal BMI (17) 9 (52.9 %) 8 (47.1 %) 8 (50.0 %) 8 (50.0 %)
χ2 = 0.10, p = 0.75 Fisher's exact: p = 0.004*
OR = 8.89, CI = 1.94–40.71
I-carriers Obese BMI (18) 9 (50.0 %) 9 (50.0 %) 15 (83.3 %) 3 (16.7 %)
Normal BMI (12) 3 (25.0 %) 9 (75.0 %) 8 (66.7 %) 4 (33.3 %)
Fisher's exact: p = 0.26 Fisher's exact: p = 0.39
DD Large WC (37) 23 (62.2 %) 14 (40.0 %) 33 (89.2 %) 4 (10.8 %)
Normal WC (13) 5 (38.5 %) 8 (53.3 %) 6 (46.2 %) 7 (53.8 %)
χ2 = 2.19, p = 0.14 Fisher's exact: p = 0.003*
OR = 9.63, CI = 2.14–43.36
I-carriers Large WC (20) 10 (50.0 %) 10 (50.0 %) 17 (85.0 %) 3 (15.0 %)
Normal WC (10) 2 (20.0 %) 8 (80.0 %) 6 (60.0 %) 5 (40.0 %)
Fisher's exact: p = 0.24 Fisher's exact: p = 0.18
DD Large WHtR (43) 25 (58.1 %) 18 (41.9 %) 36 (83.7 %) 7 (16.3 %)
Normal WHtR (7) 3 (42.9 %) 4 (57.1 %) 3 (42.9 %) 4 (57.1 %)
Fisher's exact: p = 0.68 Fisher's exact: p = 0.034*
OR = 6.86, CI = 1.25–37.61
I-carriers Large WHtR (26) 12 (46.2 %) 14 (53.8 %) 19 (73.1 %) 7 (26.9 %)
Normal WHtR (4) 0 (0 %) 4 (100 %) 4 (100 %) 0 (0 %)
Fisher's exact: p = 0.13 Fisher's exact: p = 0.55
Data are presented as number (percentage)
*: significant difference at p < 0.05
DD homozygous deletion genotype, I-carriers homozygous and heterozygous insertion genotypes, BMI: body mass index, WC waist circumference, WHtR
waist/height ratio, WHR waist/hip ratio, C-index conicity index, χ2 chi square, OR odds ratio, CI confidence intervals
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found to be significantly higher in diabetic patients in
Tunis [6, 35] and in Bahrain [36]. The ACE I allele was
found to be associated with diabetes among Kuwaitis [37].
As for association with lipid disorders, a Saudi study
revealed that ACE gene I/D polymorphism has no role
in predicting the occurrence and diagnosis of familial
hypercholesterolemia [7]. Apart from that, no other
studies were reported to investigate the association of
ACE gene I/D polymorphism with lipid disorders nor
with MetS in Arabs or Africans.
Studying the interaction between obesity and hyper-
tension, we found that WHR and C-index were the best
obesity indices to reflect hypertension, as they were sig-
nificantly higher in hypertensive patients than in normo-
tensive subjects while other obesity indices did not show
such significance (Table 4). However, cases having high
WC showed significantly higher blood pressure values than
those with normal WC (Table 5). We also checked whether
this interaction was affected by ACE I/D polymorphism.
As previously discussed, although non-significant, the DD
genotype was more prevalent than I-carriers in all cases
than in controls, whether they were obese (ON), hyperten-
sive (LH) or both (OH) (Table 3). Also, obese patients
based on having high WHR or C-index had higher risk of
being hypertensive than normal subjects, but to a similar
extent in both DD and I-carriers. On the other hand, carry-
ing the I-allele seemed more significantly protective against
hypertension in subjects with normal WHR and C-index
compared to their corresponding DD genotype counter-
parts (Table 6). It was previously reported that WHR and
C-index show great accuracy for the detection of the risk
of cardiovascular disease [38]. Fat stored in visceral depots
(indicated by higher WHR) makes obese individuals more
prone to complications than subcutaneous fat even at the
same BMI. On the contrary, larger gluteo-femoral fat
stores (indicated by smaller WHR) are protective [10].
We similarly checked the effect of ACE I/D on the inter-
action between obesity and insulin resistance. In DD
genotype carriers, a significant association was found be-
tween insulin resistance and obesity as presented by BMI,
WC and WHtR, although the variations in percentages
between DD and I-carriers were not high enough to con-
clude a clear effect of ACE I/D on such an association
(Table 6). Similarly, a study on Emiratis found no effect of
obesity status on the association of ACE genotypes with
diabetes [14]. Also, WC and BMI were previously reported
to predict type 2 diabetes [3]. On the other hand, it was
previously reported that the ACE D allele could raise dia-
betic risk in obese but not lean men [39].
A major limitation of this study is the relatively small
sample size. Therefore, extending the investigation of
the studied associations on a larger sample set is war-
ranted to confirm that the present findings would repli-
cate in other groups.
Conclusions
Angiotensin-converting enzyme insertion/deletion poly-
morphism was not significantly associated with obesity
in this sample of Egyptian females or with any of the
studied disorders related to obesity, namely hyperten-
sion, insulin resistance and metabolic syndrome, regard-
less of the apparently higher DD genotype frequencies in
obese and/or hypertensive patients compared to their
normal counterparts. However, DD genotype carriers
showed higher values of blood pressure parameters
mainly diastolic blood pressure that was almost signifi-
cant. In addition, the I allele significantly decreased the
risk of hypertension in subjects with normal, not high,
WHR and C-index in comparison to the DD genotype.
On the other hand, a clear effect of ACE I/D poly-
morphism on the association of obesity and insulin re-
sistance could not be established.
This is the first study to address the association of
ACE I/D polymorphism with obesity and related disor-
ders, specifically, hypertension, insulin resistance and
metabolic syndrome, in Egyptian females. Very few stud-
ies addressed the association of this polymorphism with
these disorders together in Arabs and Africans, but they
all studied and analyzed both sexes together, while our
study was sex-specific studying only females.
Further confirmatory studies on a larger sample num-
ber could be beneficial to support or contradict our re-
sults. We also suggest the inclusion of both males and
females, but to be analyzed separately, to check whether
ACE I/D polymorphism could justify the vast difference
in obesity prevalence observed between Egyptian males
and females.
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